TransMedics Group Sees Unusually Large Options Volume (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) was the recipient of some unusual options trading on Friday. Stock traders purchased 9,812 call options on the stock. This represents an increase of approximately 182% compared to the typical daily volume of 3,482 call options.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TMDX shares. Piper Sandler reiterated an “overweight” rating and set a $125.00 target price (up from $105.00) on shares of TransMedics Group in a research note on Friday. Oppenheimer lifted their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an “outperform” rating in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $104.00 target price on shares of TransMedics Group in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.70.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $111.50 on Friday. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm’s 50-day simple moving average is $78.53 and its 200 day simple moving average is $75.72. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of 118.62 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million for the quarter, compared to analysts’ expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same period last year, the firm earned $0.35 earnings per share. As a group, sell-side analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Braidwell LP acquired a new stake in shares of TransMedics Group during the 4th quarter worth $57,493,000. Norges Bank bought a new stake in TransMedics Group during the fourth quarter worth about $22,861,000. Mackenzie Financial Corp grew its stake in TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after buying an additional 349,403 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after buying an additional 253,624 shares during the period. Finally, Emerald Advisers LLC raised its position in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after buying an additional 220,804 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.